bioRxiv / medRxiv
open access
CC BY-NC-ND 4.0
Dihydropyridine Calcium Channel Blockers Amplify Gabapentin-Associated Dementia Risk: A Cohort Study
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sodium channel blockers are associated with reduced dementia risk in late-onset unexplained epilepsy#296511
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide#321610
- Sequence-Dependent Amplification of Gabapentinoid-Associated Dementia Risk by Dihydropyridine Calcium Channel Blockers: Asymmetric Pharmacodynamic Vulnerability Consistent with Homeostatic Synaptic Plasticity#149849
- Sequence-Dependent Amplification of Gabapentinoid-Associated Dementia Risk by Dihydropyridine Calcium Channel Blockers: Asymmetric Pharmacodynamic Vulnerability Consistent with Homeostatic Synaptic Plasticity#146540
- Key targets and mechanisms by which gut microbiota-derived metabolites regulate Alzheimer’s disease through the immune - inflammatory pathway: Based on network pharmacology and molecular docking#345382
Record · ID 10128
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive